Calcitriol - CAS 32222-06-3
Catalog number:
32222-06-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C27H44O3
Molecular Weight:
416.64
COA:
Inquire
Targets:
VD/VDR
Description:
Calcitriol is the hormonally active form of vitamin D.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
RO215535, Topitriol
MSDS:
Inquire
1.1,25-Dihydroxyvitamin D3 inhibits the proliferation of thyroid cancer stem-like cells via cell cycle arrest.
Peng W1, Wang K1, Zheng R1, Derwahl M1. Endocr Res. 2016 Mar 30:1-8. [Epub ahead of print]
BACKGROUND: An anti-proliferative effect of vitamin D has been reported in different carcinomas, including thyroid cancer. Cancer stem cells (CSCs), a very small fraction of cancer cells, are widely believed to be responsible for cancer initiation, relapse and metastasis.
2.Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
Kumar J1, Tran NG1, Schomberg J1, Streja E1, Kalantar-Zadeh K1, Pahl M2. J Ren Nutr. 2016 Mar 30. pii: S1051-2276(16)00045-5. doi: 10.1053/j.jrn.2016.02.006. [Epub ahead of print]
OBJECTIVE: The management of hyperparathyroidism in hemodialysis patients involves the administration of phosphate binders, vitamin D receptor activators, and calcimimetics. Intravenous paricalcitol has been preferred over oral calcitriol as it may cause less hypercalcemia and hyperphosphatemia. However, there is little data looking at the efficacy and tolerability of oral calcitriol in the calcimimetic era particularly in a real practice-based experience. The University of California, Irvine free-standing dialysis center converted from routine intravenous paricalcitol to oral calcitriol due to pharmacy purchasing preferences. We report the efficacy, safety, and cost of such a change.
3.Genetic Disorders Of Vitamin D Biosynthesis and Degradation.
Miller WL1. J Steroid Biochem Mol Biol. 2016 Apr 6. pii: S0960-0760(16)30097-8. doi: 10.1016/j.jsbmb.2016.04.001. [Epub ahead of print]
Vitamin D, an inactive secosteroid pro-hormone, is produced by the action of ultraviolet light on 7-dehydrocholesterol in the skin. The active hormone, 1,25(OH)2D is produced by sequential 25-hydroxylation in the liver, principally by CYP2R1, and 1α-hydroxylation in the kidney by CYP27B1. Mutations in CYP27B1 cause 1α-hydroxylase deficiency, also known as vitamin D dependent rickets type I or hereditary pseudo-vitamin D deficient rickets; very rare mutations in CYP2R1 can cause 25-hydroxylase deficienccy. Both deficiencies cause hypocalcemia, secondary hyperparathyroidism, severe rickets in infancy, and low serum concentrations of 1,25(OH)2D; both disorders respond to hormonal replacement therapy with calcitriol. The inactivation of vitamin D is principally initiated by its 23- and 24-hydroxylation by CYP24A1. Mutations in CYP24A1 can cause both severe neonatal hypercalcemia and a less severe adult hypercalcemic syndrome. Other pathways of vitamin D metabolism are under investigation, notably its 20-hydroxylation by the cholesterol side-chain cleavage enzyme, CYP11A1.
4.The Significance of Ultrasound in Determining Whether SHPT Patients Are Sensitive to Calcitriol Treatment.
Liang XX1, Li F2, Gao F2, Li CX2, Qiao XH2, Zhang JJ2, Du LF2. Biomed Res Int. 2016;2016:6193751. doi: 10.1155/2016/6193751. Epub 2016 Feb 29.
This study was to explore the significance of ultrasound in determining whether the patients with secondary hyperparathyroidism (SHPT) are sensitive to calcitriol treatment. According to the decrease value of parathyroid hormone (PTH), 42 SHPT patients were divided into two groups: drug susceptible group and drug insusceptible group. These 42 SHPT patients' ultrasound images were retrospectively analyzed. The morphology, size, number, blood flow, elastic modulus, and perfusion of the parathyroid glands were correlated with drug therapeutic outcome (oral calcitriol). Most SHPT patients with drug susceptible showed volume <438.50 mm(3) and number ≤2, with 0-1 structural and vascular patterns, associated with Relative Maximum Intensity (RIMAX) <1.59 and elastic modulus <18.8 kPa, whereas most SHPT patients with drug insusceptible showed volume ≥438.50 mm(3) and number ≥3, with 2-3 structural and vascular patterns, associated with Relative Maximum Intensity (RIMAX) ≥1.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related VD/VDR Products


CAS 112849-14-6 (24S)-MC 976

(24S)-MC 976
(CAS: 112849-14-6)

(24S)-MC 976 is a Vitamin D3 derivative.

CAS 57333-96-7 Tacalcitol

Tacalcitol
(CAS: 57333-96-7)

Tacalcitol promotes normal bone development by regulating calcium and modulates immunological and inflammatory processes. lt induces nerve growth factor product...

CAS 131918-61-1 Paricalcitol

Paricalcitol
(CAS: 131918-61-1)

Synthetic analog of vitamin D. Antihyperparathyroid.

CAS 126860-83-1 MC 1046

MC 1046
(CAS: 126860-83-1)

MC 1046 is a vitamin D3 analogue with similar effects. Impurity of Calcipotriol, an antipsoriatic.

CAS 54573-75-0 Doxercalciferol

Doxercalciferol
(CAS: 54573-75-0)

Doxercalciferol (Hectorol; 1.alpha.-Hydroxyvitamin D2) is a synthetic analog of vitamin D; is a Vitamin D2 analog that acts as a vitamin D receptor activator (V...

CAS 143032-85-3 1α-Hydroxy VD4

1α-Hydroxy VD4
(CAS: 143032-85-3)

1alpha-Hydroxy VD4 , a 1alpha(OH)D derivative,&nbsp; can effectively induce the differentiation of monoblastic leukaemia U937, P39/TSU and P31/FUJ cells.

CAS 112965-21-6 Calcipotriol

Calcipotriol
(CAS: 112965-21-6)

Calcipotriol, a 1,25-Dihydroxyvitamin D3 analogue, is used as topical treatment for psoriasis.

CAS 58050-55-8 24, 25-Dihydroxy VD2

24, 25-Dihydroxy VD2
(CAS: 58050-55-8)

24, 25-Dihydroxy VD2 is a hydroxylated metabolite of Vitamin D2, which is a synthetic analog of Vitamin D.

CAS 131875-08-6 Lexacalcitol

Lexacalcitol
(CAS: 131875-08-6)

KH1060 metabolism could be blocked by the cytochrome P450 inhibitor, ketoconazole. KH1060 was not an effective competitor of C24 oxidation of 1alpha,25-(OH)2D3....

CAS 112875-61-3 Impurity of Calcipotriol

Impurity of Calcipotriol
(CAS: 112875-61-3)

Impurity of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.

CAS 457048-34-9 1α, 24, 25-Trihydroxy VD2

1α, 24, 25-Trihydroxy VD2
(CAS: 457048-34-9)

1alpha, 24, 25-Trihydroxy VD2 is a vitamin D analog.

CAS 103909-75-7 Maxacalcitol

Maxacalcitol
(CAS: 103909-75-7)

Maxacalcitol is non-calcemic vitamin D3 analog and ligand of VDR-like receptors.

CAS 55700-58-8 (24S)-24,25-Dihydroxyvitamin D3

(24S)-24,25-Dihydroxyvitamin D3
(CAS: 55700-58-8)

(24S)-24,25-Dihydroxycholecalciferol is an inactive form of vitamin D3 which undergoes various levels of hydroxylation to form active vitamin D3 analogs.

LG190155
(CAS: 233268-78-5)

LG190155 is a moderately potent VDR agonist.

CAS 21343-40-8 Ercalcidiol

Ercalcidiol
(CAS: 21343-40-8)

A metabolite of Vitamin D2

CAS 112827-99-3 24R-Calcipotriol

24R-Calcipotriol
(CAS: 112827-99-3)

24R-Calcipotriol is an impurity of Calcipotriol, which is a ligand of VDR-like receptors.

CAS 83805-11-2 Falecalcitriol

Falecalcitriol
(CAS: 83805-11-2)

Falecalcitriol is an analog of calcitriol. It has a higher potency both in vivo and in vitro systems, and longer duration of action in vivo.

CAS 129831-99-8 MC 976

MC 976
(CAS: 129831-99-8)

MC 969 is an analog of the calcemic drug 1α-hydroxyvitamin D3 (1α-OH-D3) in which carbons 25, 26, and 27 in the side chain are incorporated into a cyclopropane ...

CAS 60133-18-8 Ercalcitriol

Ercalcitriol
(CAS: 60133-18-8)

Ercalcitriol is a active metabolite of vitamin D2. It exhibits equipotent antirachitic activity in rats as calcitriol.

CAS 19356-17-3 Calcifediol

Calcifediol
(CAS: 19356-17-3)

Calcifediol is a major circulating metabolite of vitamin D3 and acts as a competitive inhibitor with an apparent Ki of 3.9 μM. It also suppresses PTH secretion ...

Chemical Structure

CAS 32222-06-3 Calcitriol

Quick Inquiry

Verification code

Featured Items